Victory Capital Management
GALT icon

Victory Capital Management’s Galectin Therapeutics GALT Stock Holding History

Victory Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,782
Closed -$28K – 2797
2020
Q1 		$28K Buy
+14,782
New +$36K ﹤0.01% 2975
2019
Q4 		– Sell
-8,067
Closed -$30K – 2875
2019
Q3 		$30K Buy
+8,067
New +$29.2K ﹤0.01% 2902

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Victory Capital Management's GALT Position: Q2 2020 in Review

Victory Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2020, closing a stake of 14,782 shares — an estimated $28K sold.

Victory Capital Management first reported a position in GALT in Q3 2019 and held it in 2 quarters. The position peaked at $30K in Q3 2019. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2020.

  • Victory Capital Management reported no remaining Galectin Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 14,782 Galectin Therapeutics shares in Q2 2020, an estimated $28K.
  • Victory Capital Management first reported a position in Galectin Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Galectin Therapeutics position peaked at $30K in Q3 2019.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.